As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for samples received on April 20, at the Charlotte, Dallas, Phoenix, St. Louis and Tampa laboratories. Babesia is a selective pooled NAT test, required for all blood donations collected by May 2020, in 14 States and the District of Columbia. To help you understand the requirements, CTS will host a Babesia Implementation and Review webinar on March 3, 2020 at 11:00 am CST. If you are interested in attending, please contact your Customer Service Manager for invitation details.
As previously mentioned in Zika communications distributed on September 21 and October 12, 2018; ord...
We sincerely hope to see you at this year’s AABB Annual Meeting in San Antonio, TX on October ...
CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...
On July 6, 2018 the FDA released an industry guidance document for transitioning from individual to ...
At CTS, we understand the impact converting to the Ortho viral marker platform has on your operation...
The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...